Skip to content

AMN Healthcare Services

US · AMN #3031 by market cap Listed 1970
36.53 -0.20 -0.54%
Live - 5344 symbols - heartbeat 358s ago · 2026-10-08 07:21
Pre-market 36.63 +0.27%
After-hours 36.53 0.00%
Market cap
1.41B
P/B
1.91
EPS
-2.48
Reader sentiment Are you bullish or bearish on AMN?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 1.92 In line with history 41st percentile
5-year average 2.81 · #16 of 40 in Medical Care Facilities
P/E ratio 13.65 Expensive vs history 73rd percentile
5-year average 6.98 · forward -69.09 · #12 of 30 in Medical Care Facilities
P/S ratio 0.41 In line with history 38th percentile
5-year average 0.66 · forward 0.54 · #14 of 50 in Medical Care Facilities

Vs. peers Medical Care Facilities

Company Market cap P/E (TTM) P/B Div yield
AMN Healthcare Services (AMN) 1.41B 13.58 1.91 0.00%
HCA Healthcare (HCA) 95.08B 14.73 -14.32 0.68%
Tenet Healthcare (THC) 20.92B 10.04 4.49 0.00%
Encompass Health (EHC) 12.08B 19.95 4.65 0.62%
DaVita (DVA) 11.28B 14.57 -14.74 0.00%
Fresenius Medical Care (FMS) 11.01B 11.14 0.78 4.13%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value35.72 Economic moatNone UncertaintyHigh

Trading 2.2% above Morningstar's fair value estimate.

Fair value

AMN Healthcare Services Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 3% premium over our quantitative fair value estimate of $35.72 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's unfavorable dividend structure decreases our fair value estimate. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. For example, the firm's forward dividend yield of 0% falls in the bottom 30% compared with global peers. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are expensive.

Conversely, the firm's valuation metrics are reassuring. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.3, a core component of valuation, ranks in the top 40% globally. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 07:21:14 · For reference only, not investment advice and not tailored to your situation.